INFECTION DURING PREGNANCY IS LIFE THREATENING FOR BABIES
464,000 moms pass infection
to 60,000 babies every year
Causing fever
in the mom
and lung disease,
developmental delay, & death in the newborn
A $750M market opportunity addressing a $15B problem in the U.S. alone!
A $3B market opportunity addressing a $56B problem in the developed world!
Healthier moms & Babies, Fewer Complications
RAPID DIAGNOSIS
In Pregnancy, Labor
& in the Newborn ICU
EARLY TREATMENT
Penicillin for GBS
Azythromycin for Ureaplasma
Cephalosporin/Amnioglyoside for E coli
HEALTHIER PATIENTS
The right diagnosis
At the right time
For the right treatment
Vax-Immune has ENABLED rapid diagnosIS of these pathogens
during pregnancy, labor and in the Newborn ICU.
PRINCIPALS
ADVISORS
Adam Deltz, Advisor
Founder & CTO of
Ortho Kinematics
Matthew Duffy, Advisor
25 years in healthcare
marketing & sales
Gerald Fischer, MD, Advisor
Internationally recognized in
pediatric infectious diseases
Ted Holland, Advisor
18 years of biopharmaceutical
marketing experience
Jon Polanich, Advisor
Novo Nordisk, AstraZeneca,
Endo Pharmaceutics & IMS Health
Leonard E. Weisman, MD, President and Chief Technology Officer
Dr. Weisman is a seasoned inventor with formal development experience (Medimmune, Inc.- sold for $15.6 B in 2007, and Biosynexus, Inc. secured $120 M in venture capital). Practicing neonatal medicine and research for over 35 years, Professor of Pediatrics at Baylor College of Medicine with 260 academic publications and $15 M in extramural research funding. BS in Engineering, USMA West Point, M.D. Baylor College of Medicine. Dr. Weisman is a retired U. S. Army colonel.
Bhairavi Parikh, PhD, Chief Product Development Officer
Bhairavi is an experienced entrepreneur with extensive experience in medical diagnostics and women and children’s health. She has founded 3 companies including Apieron Biosystems, CellScape Corporation and CrestaBio, securing over $75MM in financing. She has a PhD in Biomedical Engineering from Worcester Polytechnic Institute and University Massachusetts Medical School.
Joaquin Altenberg, MBA, BSEE, Chief Financial Officer
Joaquin is a seasoned entrepreneur in biotechnology, technology and energy sectors and has grown companies in roles as CEO, CFO and business development. He has secured over $3.0 B in financing, and has served in investment or advisory positions with Salomon Smith Barney, Morgan Stanley, Citigroup, Lazard, and Vert Investment Group. University of Texas at Austin, B.S. in Biomedical and Computer Engineering and an MBA from Harvard Business School.
$3 BILLION: MARKET POTENTIAL
GLOBAL MISSION
RAPID DIAGNOSIS OF INFECTIOUS DISEASE IN THE DEVELOPED WORLD
NEWS
Harvard Business School Alumni
New Venture Competition
Regional Winner (Texas)
& International Finalist
Goradia Innovation
3rd Place Award
Texas Emerging Technology Fund
Gulf Coast and Dallas Regional Finalist
National Council of Entrepreneurial Tech Transfer
Present and Attend
Conference & Showcase
Disclaimer / Privacy Policy
All contents of this site including but not limited to all original text, graphics, logos, images, data, buttons, icons and the like were developed at considerable expense to and are the exclusive property of Vax-Immune, LLC. By accessing and/or browsing this Web site you hereby acknowledge that the contents are encompassed by United States and other International laws, regulations and statutes for the protection of intellectual property and other business interests including but not limited to those regarding the protection of proprietary information, patents, trademarks, service marks, trade names, trade secrets, trade dress, and copyright.
Vax-Immune | ©2016
